Navigation Links
David Barker, Former Illumina CSO, Joins GenVault's Scientific Advisory Board
Date:9/28/2007

CARLSBAD, Calif., Sept. 28 /PRNewswire/ -- GenVault Corporation today announces that industry expert David Barker Ph.D. has joined its Scientific Advisory Board. In his role on the board, Dr. Barker will provide scientific guidance facilitating GenVault's entry into new biosample management markets. Dr. Barker brings more than 20 years experience in life science product commercialization as well as experience in serving on the boards of companies such as NextBio, Cell Biosciences, and Microchip Biotechnologies.

"Dr. Barker's extraordinarily deep understanding of the industry and its future will be extremely valuable as we chart our vision. We are very honored to welcome Dr. Barker as a key member of the GenVault advisory team," said David Wellis, CEO of GenVault

"Well-characterized biological samples and their intelligent storage and retrieval are essential for discovering disease genes and biomarkers. I am pleased to be asked to participate in GenVault's creative solutions for sample management " said Dr. Barker

Dr. Barker's previous product commercialization experience includes senior positions at Illumina as Vice President and Chief Scientific Officer; Amersham Biosciences as Vice President and Chief Science Advisor and Molecular Dynamics as Vice President of Research and Business Development until its acquisition by Amersham Biosciences. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

About GenVault

GenVault is redefining the global standard in biosample workflow and storage solutions for genomic medicine, discovery and identification. The company's room temperature technology reduces costs and empowers its partners to maximize their most valuable assets. As a scalable and reliable alternative to traditional freezers and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. For more information visit us at http://www.genvault.com.

EDITORIAL CONTACTS:

David Wellis, GenVault

(760) 268-5256

dwellis@genvault.com


'/>"/>
SOURCE GenVault Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. David Brooks: Segmented nation looks for solidarity amid IT-powered niches
3. CIO Leadership Series: Rick Davidson, Manpower
4. CIO Leadership Series: David Melbye, Milwaukee Metro Sewerage District
5. CIO Leadership Series: David Cagigal, Alliant Energy
6. Former Fiserv exec to enter Business Hall of Fame
7. UW scientist, former WiCell director found stem cell company
8. Kyron appoints former AMA chairman to board
9. Genzyme sues former Bone Care employees
10. Former astronaut a leader in Wisconsin Spaceport
11. New book from former CDC CEO walks readers through innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):